Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)

Sinil Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	85,921	89,440	89,135	80,007	61,754	61,438
Other Revenue	-	-0	-	-0	-	-
Revenue	85,921	89,440	89,135	80,007	61,754	61,438
Revenue Growth (YoY)	-4.60%	0.34%	11.41%	29.56%	0.52%	1.30%
Cost of Revenue	47,289	48,774	51,565	44,362	37,313	37,234
Gross Profit	38,632	40,666	37,570	35,645	24,441	24,204
Selling, General & Admin	21,230	21,238	19,491	17,623	15,574	15,522
Research & Development	2,423	2,802	2,979	3,264	194.52	784.55
Other Operating Expenses	416.04	347.33	355.82	378.68	374.75	395.92
Operating Expenses	25,148	25,445	23,579	21,989	16,459	17,583
Operating Income	13,484	15,222	13,991	13,656	7,982	6,621
Interest Expense	-25.35	-26.97	-26.13	-6.05	-9.72	-13.24
Interest & Investment Income	1,130	1,074	849.37	352.84	184.48	224.04
Currency Exchange Gain (Loss)	81.15	43.68	-59.59	90.91	26.14	4.22
Other Non Operating Income (Expenses)	54.51	217.24	1,379	899.91	14.64	1,226
EBT Excluding Unusual Items	14,724	16,530	16,134	14,994	8,197	8,062
Gain (Loss) on Sale of Investments	-26.81	-26.81	-532.61	-478.44	115.48	-11.37
Gain (Loss) on Sale of Assets	3.72	3.72	-641.55	221.3	14	13.42
Asset Writedown	31	31	-7	-92.08	14.5	97.5
Pretax Income	14,732	16,538	14,953	14,645	8,341	8,162
Income Tax Expense	2,078	2,237	1,312	2,488	1,663	617.51
Net Income	12,654	14,301	13,641	12,157	6,679	7,544
Net Income to Common	12,654	14,301	13,641	12,157	6,679	7,544
Net Income Growth	-6.30%	4.83%	12.21%	82.02%	-11.47%	3.96%
Shares Outstanding (Basic)	12	12	12	11	11	11
Shares Outstanding (Diluted)	12	12	12	11	11	11
Shares Change (YoY)	-0.02%	-0.02%	3.94%	-1.05%	-0.11%	-2.91%
EPS (Basic)	1094.66	1237.13	1179.82	1092.89	594.11	670.34
EPS (Diluted)	1094.66	1237.13	1179.82	1092.89	594.11	670.34
EPS Growth	-6.28%	4.86%	7.95%	83.95%	-11.37%	7.08%
Free Cash Flow	10,766	12,327	1,551	3,336	7,820	2,261
Free Cash Flow Per Share	931.35	1066.39	134.13	299.94	695.63	200.87
Gross Margin	44.96%	45.47%	42.15%	44.55%	39.58%	39.40%
Operating Margin	15.69%	17.02%	15.70%	17.07%	12.93%	10.78%
Profit Margin	14.73%	15.99%	15.30%	15.20%	10.81%	12.28%
Free Cash Flow Margin	12.53%	13.78%	1.74%	4.17%	12.66%	3.68%
EBITDA	19,152	20,828	19,353	18,088	12,518	11,053
EBITDA Margin	22.29%	23.29%	21.71%	22.61%	20.27%	17.99%
D&A For EBITDA	5,668	5,607	5,361	4,432	4,536	4,432
EBIT	13,484	15,222	13,991	13,656	7,982	6,621
EBIT Margin	15.69%	17.02%	15.70%	17.07%	12.93%	10.78%
Effective Tax Rate	14.10%	13.53%	8.77%	16.99%	19.93%	7.57%
Advertising Expenses	-	980.01	1,059	762.13	157.25	206.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.